CD7 CAR-T therapy for T-cell cancers that returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type of T-cell cancer that has the CD7 marker on the cancer cells.
- You must have already tried all standard treatments (like chemo or a stem cell transplant) and they didn't work or you couldn't tolerate them.
- You are between 1 and 70 years old.
- You are generally able to care for yourself (ECOG score 0–2) and your doctor thinks you have at least 2 months to live.
- You do not have severe heart, lung, kidney, or liver failure, uncontrolled infections, other cancers, or serious mental health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This study tests a new type of immune cell therapy for people whose cancer cells have a specific marker called CD7. The treatment uses modified immune cells (CAR T-cells) to find and attack the cancer. It might help if other treatments haven't worked or the cancer has returned.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This early-stage trial tests a special immune cell treatment that targets a marker called CD7 on cancer cells, aiming to attack and destroy the cancer. It's designed for patients with blood cancers that express CD7 and who haven't had prior gene therapy.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This trial tests a new type of immunotherapy called CAR-T that targets a protein called CD7 on cancer cells. It is for people with peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.